Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 351 to 400 of 2053 results for work

  1. Your role as a NICE committee member

    a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Help us improve Help...

  2. Your role as a NICE committee member

    a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Help us improve Help...

  3. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    Awaiting development Reference number: GID-TA11500 Expected publication date: TBC

  4. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  5. How to use quality standards

    How providers and commissioners can use quality standards to improve the quality of care

  6. Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

    Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.

  7. Modern slavery and human trafficking statement

    Read NICE's statement on modern slavery and human trafficking.

  8. Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over (TA1085)

    Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

  9. Renal replacement therapy services for adults (QS72)

    This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.

  10. Payments and expenses

    Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.

  11. Payments and expenses

    Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.

  12. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  13. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  14. Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

    In development Reference number: GID-TA11162 Expected publication date:  28 July 2027

  15. Developing and updating local formularies (MPG1)

    This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.

  16. Prosthetic intervertebral disc replacement in the lumbar spine (HTG197)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the lumbar spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  17. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

  18. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

  19. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  20. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  21. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

  22. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

  23. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development Reference number: GID-TA11343 Expected publication date: TBC

  24. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

  25. Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer (TA1127)

    Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.

  26. Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management (NG237)

    This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.

  27. Study NICE and LSE's Executive MSc Healthcare Decision-Making

    Study NICE and LSE's Executive MSc Healthcare Decision-Making

  28. Study NICE and LSE's Executive MSc Healthcare Decision-Making

    Study NICE and LSE's Executive MSc Healthcare Decision-Making

  29. Dental checks: intervals between oral health reviews (CG19)

    This guideline covers assigning recall intervals between oral health reviews that are appropriate to the needs of individual patients. The guideline takes account of the effect of dental checks on: people’s wellbeing, general health and preventive habits; caries incidence and avoiding restorations; periodontal health and avoiding tooth loss; and avoiding pain and anxiety. It aims to improve or maintain patients’ quality of life and reduce morbidity associated with oral and dental disease.

  30. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215)

    This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.

  31. Decision-making and mental capacity (NG108)

    This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

  32. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services (CG138)

    This guideline covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care.

  33. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input

  34. Timeline for developing quality standards

    The key stages in development of our quality standards

  35. Guidance executive

    NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.

  36. Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.

  37. Accessing NHS care and treatment recommended by NICE (ECD4)

    This document contains advice to help you access treatments and care that NICE has recommended

  38. Depression in children and young people: identification and management (NG134)

    This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.

  39. Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

    Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.

  40. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)

    Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.

  41. Abdominal aortic aneurysm: diagnosis and management (NG156)

    This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.

  42. Technologies to support the rapid diagnosis of endometriosis (provisional title)

    In development Reference number: GID-HTE10082 Expected publication date: TBC

  43. Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

    This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.

  44. NICE newsletters and alerts

    Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

  45. The NICE public health guidance development process (third edition) (PMG5)

    This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages

  46. Antisocial personality disorder: prevention and management (CG77)

    This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.

  47. Rheumatoid arthritis in over 16s (QS33)

    This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.

  48. Diabetes in pregnancy (QS109)

    This quality standard covers managing diabetes and its complications in women who are planning a pregnancy or are already pregnant. It includes care for women with pre-existing diabetes before and during pregnancy, and diagnosis and management of gestational diabetes. It describes high-quality care in priority areas for improvement.

  49. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation.